Despite recent declines, opioids remain commonly prescribed to about one in five \us adults who live with chronic pain as ...

Following on from the San Francisco-based firm’s attempts to sell compounded GLP-1 agonists to the weight loss market—whether ...

US drugmaker Merck & Co, known as MSD outside of North America, has scrapped a £1 billion ($1.35 billion) research center in ...

The Trump administration is weighing a draft executive order that could block the import of Chinese-made experimental ...

A new analysis from Phesi of 583 recruiting clinical trials or trials about to start involving GLP-1 receptor antagonists ...

The Trump administration has announced its intent to levy tariffs on pharmaceutical products and proposed lowering drug prices in the USA to most-favored nation prices. Based on recent trade deals ...

Danish CNS specialist Lundbeck is flexing its muscles in the competitive migraine space with a comprehensive collection of datasets being presented at the 2025 International Headache Congress, ...

Europe’s health technology assessment regime has entered a new era. Since January 2025, oncology drugs and advanced therapies ...

Japan’s largest drugmaker Takeda has presented data from two global Phase III double-blind, placebo-controlled studies of ...

Cambridge, USA-based CAMP4 Therapeutics today announced that it has entered into definitive securities purchase agreements ...

The Chinese National Medical Products Administration (NMPA) has approved Sanofi’s (Euronext: SAN) Tzield (teplizumab). This makes it the first disease-modifying therapy in autoimmune type 1 diabetes ...

The US Food and Drug Administration has approved Janssen Biotech’s Inlexzo (gemcitabine) intravesical system for adults with ...